Humoral and Cellular Immune Response Elicited by MRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4...

Background: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count.

Methods: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used.

Findings: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters.

Conclusion: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.

Citing Articles

Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count.

Ha N, Kim A, Jeong H, Cheon S, Park C, Choe J J Korean Med Sci. 2025; 40(9):e28.

PMID: 40065712 PMC: 11893351. DOI: 10.3346/jkms.2025.40.e28.

Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1.

Schmidt K, Geissler P, Schuster E, Schulein C, Harrer E, Schonau V iScience. 2025; 28(3):111949.

PMID: 40034846 PMC: 11872457. DOI: 10.1016/j.isci.2025.111949.

Assessing Torquetenovirus (TTV) as a Biomarker for Immune Responses to SARS-CoV-2 mRNA Vaccines in People Living with HIV and Healthy Individuals.

Minosse C, Spezia P, Mazzotta V, Matusali G, Meschi S, Colavita F Vaccines (Basel). 2025; 13(2).

PMID: 40006700 PMC: 11861181. DOI: 10.3390/vaccines13020153.

Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study.

Yendewa G, Olasehinde T, Mulindwa F, Salata R, Mohareb A, Jacobson J Open Forum Infect Dis. 2025; 12(2):ofaf013.

PMID: 39896985 PMC: 11786054. DOI: 10.1093/ofid/ofaf013.

COVID-19 Vaccinations, Infections, and Outcomes Among 784 People Living with HIV.

Mahlab-Guri K, Komarova I, Kadar L, Nemet S, Cohen R, Radian-Sade S Viruses. 2025; 16(12.

PMID: 39772116 PMC: 11680229. DOI: 10.3390/v16121805.

References

Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A . Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010; 24(14):2187-92. DOI: 10.1097/QAD.0b013e32833c6d5c. View

Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D . Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020; 183(4):996-1012.e19. PMC: 7494270. DOI: 10.1016/j.cell.2020.09.038. View

Agrati C, Castilletti C, Goletti D, Meschi S, Sacchi A, Matusali G . Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms. 2021; 9(6). PMC: 8235087. DOI: 10.3390/microorganisms9061315. View

Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021; 27(12):1851-1855. PMC: 8382485. DOI: 10.1016/j.cmi.2021.07.031. View

Koff W, Schenkelberg T, Williams T, Baric R, McDermott A, Cameron C . Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med. 2021; 13(579). DOI: 10.1126/scitranslmed.abd1525. View

Spinelli M, Lynch K, Yun C, Glidden D, Peluso M, Henrich T . SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 2021; 8(6):e334-e341. PMC: 8084354. DOI: 10.1016/S2352-3018(21)00072-2. View

Moor M, Suter-Riniker F, Horn M, Aeberli D, Amsler J, Moller B . Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021; 3(11):e789-e797. PMC: 8423431. DOI: 10.1016/S2665-9913(21)00251-4. View

Ruddy J, Boyarsky B, Bailey J, Karaba A, Garonzik-Wang J, Segev D . Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS. 2021; 35(14):2399-2401. PMC: 10323870. DOI: 10.1097/QAD.0000000000003017. View

Hod T, Ben-David A, Olmer L, Levy I, Ghinea R, Mor E . Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies. Transplantation. 2021; 105(11):e234-e243. PMC: 8549122. DOI: 10.1097/TP.0000000000003889. View

10.

Krause P, Fleming T, Peto R, Longini I, Figueroa J, Sterne J . Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021; 398(10308):1377-1380. PMC: 8437678. DOI: 10.1016/S0140-6736(21)02046-8. View

11.

Frater J, Ewer K, Ogbe A, Pace M, Adele S, Adland E . Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021; 8(8):e474-e485. PMC: 8213361. DOI: 10.1016/S2352-3018(21)00103-X. View

12.

Paiardini M, Muller-Trutwin M . HIV-associated chronic immune activation. Immunol Rev. 2013; 254(1):78-101. PMC: 3729961. DOI: 10.1111/imr.12079. View

13.

Deeks S, Lewin S, Havlir D . The end of AIDS: HIV infection as a chronic disease. Lancet. 2013; 382(9903):1525-33. PMC: 4058441. DOI: 10.1016/S0140-6736(13)61809-7. View

14.

Matusali G, Colavita F, Lapa D, Meschi S, Bordi L, Piselli P . SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses. 2021; 13(4). PMC: 8069482. DOI: 10.3390/v13040655. View

15.

Boyarsky B, Werbel W, Avery R, Tobian A, Massie A, Segev D . Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA. 2021; 325(17):1784-1786. PMC: 7961463. DOI: 10.1001/jama.2021.4385. View

16.

Madhi S, Koen A, Izu A, Fairlie L, Cutland C, Baillie V . Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021; 8(9):e568-e580. PMC: 8372504. DOI: 10.1016/S2352-3018(21)00157-0. View

17.

Collier A, Corey L, Murphy V, Handsfield H . Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988; 109(2):101-5. DOI: 10.7326/0003-4819-109-2-101. View

18.

Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View

19.

Woldemeskel B, Karaba A, Garliss C, Beck E, Wang K, Laeyendecker O . The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021; 74(7):1268-1270. PMC: 8406881. DOI: 10.1093/cid/ciab648. View

20.

Serrano-Villar S, Sainz T, Lee S, Hunt P, Sinclair E, Shacklett B . HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014; 10(5):e1004078. PMC: 4022662. DOI: 10.1371/journal.ppat.1004078. View